Tibet AIM Pharm. Inc. (SHE:002826)

Market Cap	3.39B +85.6%
Revenue (ttm)	670.32M +4.7%
Net Income	93.44M +153.7%
EPS	0.52 +161.7%
Shares Out	190.07M
PE Ratio	35.62
Forward PE	n/a
Dividend	0.15 (0.82%)
Ex-Dividend Date	Jun 24, 2025

Volume	3,365,700
Average Volume	5,085,413
Open	18.67
Previous Close	18.33
Day's Range	17.80 - 18.67
52-Week Range	11.50 - 26.83
Beta	0.42
RSI	31.40
Earnings Date	Apr 28, 2026

About Tibet AIM Pharm.

Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company’s products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; gynecology and obstetrics; and NalMefene hydrochloride injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, severe infection, shock, cord injury, and brain, as well as coma, spinal cord injury, ce...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2003
• Employees: 403
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002826

Financial Performance

In 2025, Tibet AIM Pharm.'s revenue was 636.27 million, a decrease of -2.39% compared to the previous year's 651.88 million. Earnings were 92.58 million, an increase of 101.57%.